Group 1: Market Overview - The Hang Seng Index fell by 0.61%, down 157 points, closing at 25,460 points, while the Hang Seng Tech Index dropped by 1.78% [1] - The early trading volume in the Hong Kong stock market reached HKD 183.6 billion [1] Group 2: Banking Sector Performance - Chinese banks showed a significant recovery in performance for the first half of the year, attracting insurance capital inflows amid asset scarcity [1] - Chongqing Rural Commercial Bank rose by 4.15%, Agricultural Bank of China increased by 3.65%, and Postal Savings Bank of China gained 2.50% [1] Group 3: Notable Stock Movements - Haotian International Investment surged over 11% as its subsidiary plans to apply for virtual asset trading services [1] - Yunfeng Financial increased by over 8% following a strategic cooperation agreement with Ant Group and investment in Pharos blockchain [1] - China Nonferrous Mining rose over 4% due to rising copper prices improving mid-term performance [1] - Saint Noble Pharmaceutical-B saw a mid-day increase of over 10%, with a 91% year-on-year reduction in shareholder losses [1] - Hualing Pharmaceutical-B gained 2.67%, achieving its first profit in the first half of the year [1] Group 4: Declining Stocks - Chenming Paper Industry fell over 5% due to ongoing production line maintenance, reporting a loss exceeding CNY 3.8 billion for the first half [2] - ZTE Corporation dropped over 8% as its mid-term gross margin significantly declined, with analysts suggesting market optimism was excessive [2] - JS Global Life fell over 8%, reporting a shareholder loss of USD 5,924.2 million and a decrease in gross margin from third-party sales [3] - New Quality Digital plummeted over 11%, with its stock price halved in three trading days due to forced sale of shares by an executive [4]

Group 1: Hong Kong Stock Market Performance - Midea Group (00300) increased nearly 3% with Q2 revenue of 123.9 billion yuan, a year-on-year increase of 11.0%, and net profit of 13.59 billion yuan, up 15.1%. This marks the company's first interim dividend of 5 yuan per 10 shares (tax included) [2] - Sanofi (02257) saw a midday increase of over 12% as its mid-term shareholder loss narrowed by 91%, with STP705 expected to complete commercialization within the year [2] - Ocean Park (02255) rose nearly 3% in early trading, but reported a 14.2% year-on-year decline in revenue to 686 million yuan, with a loss of approximately 296 million yuan due to decreased visitor numbers and consumer spending [2] Group 2: Company Highlights - InnoCare Pharma (02577) increased over 6% with a sales revenue of 553 million yuan, a year-on-year growth of 43.4%, and a gross margin of 6.8%, marking a significant improvement of 28.4 percentage points [3] - Geekplus (02590) rose over 5%, achieving over 30% year-on-year revenue growth as a leader in global warehouse fulfillment AMR [3] - China Nonferrous Mining (01258) increased over 3.8% due to rising copper prices improving mid-term performance, with ongoing resource expansion and acquisitions [3] Group 3: Other Notable Movements - Hengrui Medicine (01276) rose over 1.5% after receiving drug registration approval for EZH2 inhibitor [3] - Horizon Robotics (09660) fell nearly 1% despite exceeding market expectations in revenue, with Goldman Sachs maintaining a positive outlook on HSD system mass production [3] - BYD Electronics (00285) dropped over 0.5% with a nearly 14% year-on-year increase in net profit, accelerating its layout in AI data centers and robotics [3] - Shandong Gold (01787) fell nearly 2% as it plans to raise approximately 3.9 billion HKD through a discounted placement to repay company debts [3]

Group 1 - The stock of Sanofi Pharmaceuticals-B (02257) increased by over 17% during trading, with a current rise of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] - Sanofi Pharmaceuticals-B reported a significant decline in other income, which amounted to USD 12.4 thousand, a year-on-year decrease of 87.4%. The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year narrowing of 91% [1] - The reduction in losses is attributed to several factors, including a decrease in fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and a decrease in fair value losses on financial liabilities [1] Group 2 - Sanofi Pharmaceuticals-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 is a dual-target siRNA that simultaneously targets TGF-β1 and COX-2, and it is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results. In the Phase II trial for basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding the indications for STP705, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer. Additionally, STP705 has received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]

Core Insights - Sanofi Pharmaceutical-B (02257) experienced a significant stock price increase, rising over 17% during trading, with a current increase of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] Financial Performance - For the first half of 2025, Sanofi Pharmaceutical-B reported other income of USD 12.4 thousand, a year-on-year decline of 87.4% [1] - The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year reduction of 91% [1] - The basic loss per share was USD 0.04 [1] - The reduction in losses was attributed to decreased fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and decreased fair value losses on financial liabilities [1] Product Pipeline - Sanofi Pharmaceutical-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 targets both TGF-β1 and COX-2, making it the first and only siRNA drug to achieve positive Phase II clinical results in cancer treatment [2] - In the Phase II clinical trial for skin basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding STP705's indications, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer [2] - STP705 has also received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]

Core Points - The company announced the resignation of Ms. Huang Mengying from various board positions effective December 1, 2025, to focus on decentralized life sciences and expanding her law firm in China [1] - Dr. Yin Huijun has been appointed as a non-executive director effective September 1, 2025 [1] - Ms. Lu Yihsing has been appointed as an independent non-executive director effective September 1, 2025 [1] - Dr. Pan Honghui, the current executive director and CEO, will become the chairman of the board effective December 1, 2025 [1] Board Composition Changes - Dr. Pan has been appointed as the authorized representative effective December 1, 2025 [1] - Mr. Ouyang Yunlong has been appointed as a member of the audit and remuneration committees effective September 1, 2025 [1] - Mr. Wang Yushan has been appointed as a member of the remuneration and investigation committees effective September 1, 2025 [1] - Dr. Zhang Peng has been appointed as the chairman of the remuneration committee effective December 1, 2025, and as a member of the nomination and investigation committees effective September 1, 2025 [1] - Ms. Lu has been appointed as the chairman of the nomination committee effective October 18, 2025, the chairman of the investigation committee effective December 1, 2025, and as a member of the audit committee effective September 1, 2025 [1]

Group 1 - The company announced the resignation of Huang Mengying from various positions including independent non-executive director and chairman of the board, effective December 1, 2025, to focus on decentralized life sciences and expand her law firm in China [1] - Yin Huijun has been appointed as a non-executive director effective September 1, 2025 [1] - Lu Yixing has been appointed as an independent non-executive director effective September 1, 2025 [1] - The current executive director and CEO, Pan Honghui, will become the chairman of the board effective December 1, 2025 [1]

Core Viewpoint - The announcement details significant changes in the board of directors at Sanofi Pharmaceuticals-B (02257), including resignations and new appointments, effective from various dates in 2025 [1]. Group 1: Board Resignation - Ms. Huang Mengying has resigned from multiple positions including independent non-executive director and chairman of the board, effective December 1, 2025, to focus on decentralized life sciences and expand her law firm in China [1]. - After her resignation, Ms. Huang will remain as a company advisor [1]. Group 2: New Appointments - Dr. Yin Huijun has been appointed as a non-executive director, effective September 1, 2025 [1]. - Ms. Lu Yixing, OBE, has been appointed as an independent non-executive director, effective September 1, 2025 [1]. - Dr. Pan Honghui, the current executive director and CEO, will become the chairman of the board, effective December 1, 2025 [1]. Group 3: Committee Changes - Dr. Pan has also been appointed as the authorized representative, effective December 1, 2025 [1]. - Mr. Ouyang Yunlong has been appointed as a member of the audit and remuneration committees, effective September 1, 2025 [1]. - Mr. Wang Yushan has been appointed as a member of the remuneration and investigation committees, effective September 1, 2025 [1]. - Dr. Zhang Peng has been appointed as the chairman of the remuneration committee, effective December 1, 2025, and as a member of the nomination and investigation committees, effective September 1, 2025 [1]. - Ms. Lu has been appointed as the chairman of the nomination committee, effective October 18, 2025, the chairman of the investigation committee, effective December 1, 2025, and as a member of the audit committee, effective September 1, 2025 [1].

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 （ 於開曼群島註冊成立的有限公司） （股份代號：2257） 獨立非執行董事辭任、委任非執行董事、獨立非執行董事、 董事會主席變更、董事委員會成員變動及授權代表變更 Sirnaomics Ltd.（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈以下變動： 獨立非執行董事辭任 Sirnaomics Ltd. 聖 諾 醫 藥 * 董事會 謹此宣佈 ，董事會已 接獲黃夢 瑩女士（「黃女士」）的辭任 函，由於黃 女 士 欲投 放 更 多 時 間於 去 中 心 化生 命 科 學 領 域及 擴 大 彼 於 中國 的 律 師 事務 所 規模 ，故 辭任 獨立 非執 行董 事、 董事 會主 席、 董事 會薪 酬委 員會（「薪酬 委 ...

Sirnaomics Ltd. 聖 諾 醫 藥 * 獨立非執行董事 黃夢瑩女士 （ 董事會主席 ） 于常海博士 王宇山先生 張鵬博士 盧懿杏女士 – 1 – 董事名單及其角色及職能 Sirnaomics Ltd.董事（「董事」）會（「董事會」）成員載列如下： 執行董事 潘洪輝博士 （ 首席執行官 ） 非執行董事 歐陽雲龍先生 殷惠軍博士 （ 於開曼群島註冊成立的有限公司） （股份代號：2257） * 僅供識別 – 2 – 董 事 會設 有 三 個 委 員會 。 下 表 載列 各 董 事 在 該等 委 員 會 中 所擔 任 角 色 之資 料。 | 董事 | | 董事委員會 | | | --- | --- | --- | --- | | | 審核委員會 | 提名委員會 | 薪酬委員會 | | 潘洪輝博士 | — | M | — | | 歐陽雲龍先生 | M | — | M | | 黃夢瑩女士 | M | M | C | | 于常海博士 | M | C | M | | 王宇山先生 | C | — | M | | 張鵬博士 | — | M | — | | 盧懿杏女士 | M | — | — | 附註： C 有關董事委 ...

智通财经APP讯，圣诺医药-B(02257)发布2025年中期业绩，其他收入12.4万美元，同比下降87.4%;公司 拥有人应占亏损369.8万美元，同比收窄91%;每股基本亏损0.04美元。 期内亏损减少主要归因于：截至2025年6月30日止六个月，按公平值计入损益的金融资产公平值变动亏 损减少;研发开支减少;行政开支减少;及按公平值计入损益的金融负债公平值变动亏损减少。 ...